 Kazia Therapeutics Limited ASX: KZA; NASDAQ: KZIA, an Australian oncology-focused biotechnology company, is pleased to share a poster presentation of interim data from the ongoing phase II study of paxalisib formerly GDC-0084 in glioblastoma, the most common and most aggressive form of primary brain cancer. Top-line data from this interim analysis was previously announced to ASX on 7 April 2020. 